Business Description
RemeGen Co Ltd
ISIN : CNE1000048G6
Share Class Description:
REGMF: Class HTotal Employee Number:
3,048Compare
Compare
Traded in other countries / regions
09995.Hong Kong688331.ChinaREG.GermanyREGMF.USA IPO Date
2020-12-21Description
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.08 | |||||
Equity-to-Asset | 0.5 | |||||
Debt-to-Equity | 0.61 | |||||
Debt-to-EBITDA | 1.63 | |||||
Interest Coverage | 19.96 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 11.13 | |||||
Beneish M-Score | -1.54 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 59.2 | |||||
3-Year FCF Growth Rate | 58.8 | |||||
3-Year Book Growth Rate | -11.5 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 19.99 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 38.4 | |||||
9-Day RSI | 54.34 | |||||
14-Day RSI | 61.5 | |||||
3-1 Month Momentum % | 10.05 | |||||
6-1 Month Momentum % | 22.83 | |||||
12-1 Month Momentum % | 138.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.43 | |||||
Quick Ratio | 1.19 | |||||
Cash Ratio | 0.85 | |||||
Days Inventory | 927.13 | |||||
Days Sales Outstanding | 64 | |||||
Days Payable | 302.25 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.2 | |||||
Shareholder Yield % | -1.2 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 88.13 | |||||
Operating Margin % | 26.26 | |||||
Net Margin % | 54.15 | |||||
EBITDA Margin % | 63.03 | |||||
FCF Margin % | -3.68 | |||||
OCF Margin % | 2.44 | |||||
ROE % | 45.7 | |||||
ROA % | 19.13 | |||||
ROIC % | 11.31 | |||||
3-Year ROIIC % | 64.69 | |||||
ROC (Joel Greenblatt) % | 37.59 | |||||
ROCE % | 33.93 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 35.88 | |||||
Forward PE Ratio | 15.14 | |||||
PE Ratio without NRI | 79.87 | |||||
PS Ratio | 19.67 | |||||
PB Ratio | 11.89 | |||||
Price-to-Tangible-Book | 12.42 | |||||
Price-to-Operating-Cash-Flow | 800.95 | |||||
EV-to-EBIT | 54 | |||||
EV-to-EBITDA | 47.55 | |||||
EV-to-Revenue | 29.97 | |||||
EV-to-Forward-Revenue | 6.31 | |||||
EV-to-FCF | -814.28 | |||||
Price-to-GF-Value | 0.64 | |||||
Price-to-Graham-Number | 13.69 | |||||
| Price-to-Net-Current-Asset-Value | 120.5 | |||||
Earnings Yield (Greenblatt) % | 1.85 | |||||
FCF Yield % | -0.12 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:REGMF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
RemeGen Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 304.195 | ||
| EPS (TTM) ($) | 0.302 | ||
| Beta | -1.0876 | ||
| 3-Year Sharpe Ratio | 0.58 | ||
| 3-Year Sortino Ratio | 2.99 | ||
| Volatility % | 117.71 | ||
| 14-Day RSI | 61.5 | ||
| 14-Day ATR ($) | 0.009677 | ||
| 20-Day SMA ($) | 12.05 | ||
| 12-1 Month Momentum % | 138.14 | ||
| 52-Week Range ($) | 5.06 - 12.85 | ||
| Shares Outstanding (Mil) | 563.52 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
RemeGen Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
RemeGen Co Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-10-30 | In 111 days | ||
| Second quarter earnings results for 2026 | 2026-08-21 | In 41 days | ||
| General meeting for 2025 | 2026-06-26 14:00 | 12.05 (+0.00%) | ||
| General meeting for 2025 | 2026-06-16 14:00 | 12.05 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-04-29 | 10.95 (+0.00%) | ||
| Annual report for 2025 | 2026-03-28 | 10.95 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-27 | 10.95 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-10-31 | 10.76 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-23 | 5.06 (+0.00%) | ||
| General meeting for 2024 | 2025-06-26 14:00 | 5.06 (+0.00%) |
Show
Entries
RemeGen Co Ltd Frequently Asked Questions
What is RemeGen Co Ltd(REGMF)'s stock price today?
The current price of REGMF is $12.05. The 52 week high of REGMF is $12.85 and 52 week low is $5.06.
When is next earnings date of RemeGen Co Ltd(REGMF)?
The next earnings date of RemeGen Co Ltd(REGMF) is 2026-08-21 Est..
Does RemeGen Co Ltd(REGMF) pay dividends? If so, how much?
RemeGen Co Ltd(REGMF) does not pay dividend.
Guru Commentaries on OTCPK:REGMF
No articles.
Press Release
Articles on RemeGen Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers